Expedited Programs for Drug Registration in China

by Grace Wang
Aug 16, 2021

According to China's Administrative Measures for Drug Registration enacted since July 1, 2020, the National Medical Products Administration (NMPA) shall launch expedited programs for drug registration to support clinical-value-oriented innovation in drugs.1

Grace Wang
ChemLinked Regulatory Analyst
Copyright: unless otherwise stated all contents of this website are ©2021 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact